Search the Newsreel

Top Webster Financial (WBS) Competitors 2026

Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded Emergent BioSolutions (NYSE:EBS) to a "Hold" rating. Despite beating Q2 earnings estimates, the company faces analyst forecasts for a full-year loss, increased competition, and pricing pressure, leading to a significant impairment charge against its NARCAN franchise. The stock currently has a …

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 5 p.m. ET CALL PARTICIPANTS Vice President and Treasurer - Frank VargoPresident and Chief Executive Officer - Joseph C. Papa Jr.Executive Vice President and Chief Financial Officer - Richard S. Lindahl TAKEAWAYS Total …

Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings

Emergent BioSolutions' Executive Vice President and Chief Growth Officer, Stephanie Duatschek, has reported her initial equity holdings, which include 197,416 shares of common stock and various employee stock options. Her holdings comprise 55,639 direct common shares and 141,777 unvested Restricted Stock Units (RSUs), with …

Webster Financial Corp (WBS) Stock News Today

Webster Financial (WBS): Buy, Sell, or Hold Post Q2 Earnings?

Webster Financial (WBS): Buy, Sell, or Hold Post Q2 Earnings? Webster Financial has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.3% to $79.06 per share while the index has …

Temple & Webster Group Ltd (ASX:TPW) Share Price Falls as Investors Track Profitability and Growth Balance

NetDragon Schedules Board Meeting to Approve 2026 Interim Results and Consider Dividend

Webster Financial Corporation (NYSE:WBS) Receives Consensus Recommendation of "Hold" from Analysts

Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades

Trade Desk, Papa John's, and Emergent BioSolutions all hit 52-week lows following disappointing quarterly results and subsequent analyst downgrades. Trade Desk faced a significant downgrade after missing revenue estimates and providing weak guidance, while Papa John's experienced a revenue decline despite an earnings beat. …

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions

SueWallSt, powered by Levi & Korsinsky LLP, has announced an investigation into potential securities law violations by Emergent BioSolutions (NYSE: EBS). This follows Emergent BioSolutions lowering its FY2026 adjusted EBITDA guidance and recording a significant non-cash NARCAN impairment due to increased competition and pricing …

Royal Bank of Canada Trims Stock Position in Webster Financial Corporation $WBS

NetDragon Details Share Award Grant to Executive Director in Annual Report Update

Websol Energy Q1 Profit Rises 16% to ₹77.8 Cr; Income Up

Websol Energy System posts ₹78 Cr profit in Q1FY27 as revenue jumps 70%

Emergent BioSolutions cuts FY2026 revenue forecast, triggering securities investigation.

Emergent BioSolutions has significantly lowered its FY2026 revenue guidance, leading to a sharp decline in its stock price and a securities investigation by Levi & Korsinsky. The law firm is examining whether the company's prior optimistic forecasts were misleading, encouraging investors who suffered losses …

Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS)

Levi & Korsinsky, LLP is investigating Emergent BioSolutions (EBS) for potential securities law violations after the company significantly cut its FY2026 revenue guidance. The firm encourages investors who lost money on EBS shares to submit their loss information for a free evaluation of their …

Websol Energy System Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Temple & Webster (ASX:TPW) Falls As Consumer Nerves Hit Growth Stocks

H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook

H.C. Wainwright has reduced its price target for Emergent BioSolutions (NYSE:EBS) to $10 from $12, while maintaining a Buy rating, due to a lowered full-year 2026 revenue guidance. The company's NARCAN sales have declined significantly due to new competition in the naloxone market, despite …

Webster Financial Corp's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Sustainability and Growth of WBS's Quarterly Payout Webster Financial Corp (NYSE:WBS) recently announced a total dividend of $0.4 per share, with the ex-dividend date set for 2026-08-10. This includes a $0.4 per share cash dividend payable …

Temple & Webster Group Limited (TPW.AX) stock price, news, quote and history

Webster Financial (WBS) Declares Dividend And Posts Solid EPS, Is The Stock Now Pricey?

Emergent BioSolutions Inc (EBS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Emergent BioSolutions Inc (EBS) Stock News Today

This article provides the latest stock news for Emergent BioSolutions Inc (EBS), including its recent earnings report. The company experienced MCM growth but also reported NARCAN impairment in its Q2 2026 earnings. The stock closed at $4.840, down 9.23%.

Emergent Biosolutions Q2 Earnings Call Highlights

Key Points Interested in Emergent Biosolutions Inc.? Here are five stocks we like better. Q2 performance exceeded expectations: Revenue reached $234 million and adjusted EBITDA rose to $97 million, driven by accelerated medical countermeasure deliveries and strong U.S. government contract activity. NARCAN competition is …

Emergent BioSolutions (EBS) Stock Sinks As NARCAN Impairment Deepens Losses

Emergent BioSolutions (EBS) saw its stock drop 8.9% after reporting a Q2 net loss of US$180.2 million, primarily due to a significant non-cash impairment related to NARCAN. While its Medical Countermeasures business showed strong revenue growth and adjusted EBITDA, concerns were raised about balance …

Pacer Advisors Inc. Purchases Shares of 416,191 Emergent Biosolutions Inc. $EBS

Pacer Advisors Inc. recently acquired 416,191 shares of Emergent BioSolutions (NYSE:EBS) worth approximately $3.45 million, bringing its stake to 0.81%. This purchase comes despite Emergent BioSolutions reporting a strong Q2 earnings beat, as the stock subsequently fell 29.6% due to management cutting full-year and …

Dimensional Fund Advisors LP Has $22.88 Million Position in Emergent Biosolutions Inc. $EBS

Dimensional Fund Advisors LP increased its stake in Emergent Biosolutions Inc. by 22.4% to 2.76 million shares, now valued at approximately $22.9 million, making up 5.34% of the company. Despite beating Q2 earnings and revenue estimates, Emergent's stock has fallen 29.6% due to negative …

Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 125.99% Potential Upside

Emergent BioSolutions Inc. (EBS), a healthcare company specializing in drug manufacturing for public health threats, shows a significant 125.99% potential upside according to analysts, despite a current stock price at the lower end of its 52-week range. The company boasts impressive revenue growth of …

Webster Financial Corporation (WBS) Stock Forecasts

Argus has raised its target price for Webster Financial Corporation (WBS) to $87.00. Webster Financial Corp is a full-service financial services provider offering commercial and consumer banking, mortgages, and investment advisory services across several Northeastern states. The current price for WBS is $78.78.

Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts